title: The beneficial effect of interleukin-12 on arthritis induced by group B streptococci is mediated by interferon-gamma and interleukin-10 production.
abstract: OBJECTIVE
  To assess the effect of interleukin-12 (IL-12) administration on the evolution of systemic infection and septic arthritis induced by group B streptococci (GBS) in mice.
  
  
  METHODS
  CD1 mice were inoculated intravenously with arthritogenic strain 1/82 of type IV GBS. Exogenous murine IL-12 was administered intraperitoneally 18 hours or 5 days after infection with 1 x 10(7) GBS, at doses ranging from 0.5 to 2.5 microg per mouse. Mice were monitored daily for survival and for signs of arthritis. In a subsequent set of experiments, mice were killed at selected times for examination of bacterial clearance, histopathologic changes in the joints, and cytokine production.
  
  
  RESULTS
  IL-12 administration before the onset of clinical signs had a beneficial effect on GBS-induced arthritis and was clearly dose-dependent. The 2.5-microg dose per mouse totally prevented death from GBS-induced arthritis. The decrease in pathology was associated with a reduction of the bacterial burden and a change in the cytokine profile. In particular, systemic and joint levels of interferon-gamma (IFN gamma) and IL-10 significantly increased in mice treated with IL-12, whereas a decrease in IL-6 and IL-1 beta production was observed. The beneficial effects of IL-12, in terms of the incidence and severity of articular lesions, were reversed by coadministration of anti-IFN gamma or anti-IL-10-neutralizing antibodies.
  
  
  CONCLUSIONS
  The findings of this study demonstrate that IL-12 is important in controlling the cytokine production that leads to the evolution of GBS-induced experimental arthritis. The amelioration of articular lesions is mostly attributable to IL-12-induced IFN gamma, but with a relevant participation of IL-12-induced IL-10.
authors.affiliation: University of Perugia, Perugia, Italy.
authors.forename: Manuela
authors.initials: M
authors.lastname: Puliti
authors.forename: Christina
authors.initials: C
authors.lastname: von Hunolstein
authors.forename: Francesco
authors.initials: F
authors.lastname: Bistoni
authors.forename: Paolo
authors.initials: P
authors.lastname: Mosci
authors.forename: Graziella
authors.initials: G
authors.lastname: Orefici
authors.forename: Luciana
authors.initials: L
authors.lastname: Tissi
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D021461:Animals, Outbred Strains; D001170:Arthritis, Infectious / Q000188:drug therapy* / Q000382:microbiology* / Q000401:mortality / Q000503:physiopathology; D001769:Blood / Q000382:microbiology; D005260:Female; D007371:Interferon-gamma / Q000096:biosynthesis* / Q000502:physiology; D016753:Interleukin-10 / Q000096:biosynthesis* / Q000502:physiology; D018664:Interleukin-12 / Q000627:therapeutic use*; D007596:Joints / Q000187:drug effects / Q000378:metabolism / Q000382:microbiology; D007958:Leukocyte Count; D051379:Mice; D013290:Streptococcal Infections; D013292:Streptococcus agalactiae / Q000302:isolation & purification
chemical_list: D000276:Adjuvants, Immunologic; D016753:Interleukin-10; D018664:Interleukin-12; D007371:Interferon-gamma